Ultragenyx Pharma (RARE) Tops Q2 EPS by $1.95, Revenue Beat; Offers FY20 Crysvita Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. SPY
10. FISV

Go back to Ultragenyx Pharma (RARE) Tops Q2 EPS by $1.95, Revenue Beat; Offers FY20 Crysvita Outlook

Ultragenyx Reports Second Quarter 2020 Financial Results and Corporate Update

July 30, 2020 4:04 PM EDT

Two U.S. FDA approvals in second quarter 2020

Second quarter 2020 total revenue of $61.7 million and Crysvita revenue in Ultragenyx territories of $32.4 million

Maintains full year 2020 guidance based on global COVID-19 impact to date

NOVATO, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended June 30, 2020 and maintained its full year 2020 financial guidance for... More